# Daily Iteration Report — 2026-05-20 (Wednesday)

## Summary
Continued systematic claims-checking of VETTED corpus (now 173/270 done, +15 today),
early audit of Gap #14 (BRONZE retained), DAPAN-DIA topic check, credibility sweep
(CLEAN), and pipeline rebuild (41/41 [OK]).

## Queue Items Processed

### 1. Claims-Check Batch (15 PMIDs)
Verified via PubMed eutils metadata-match (title/journal/year):
`11095109, 11484077, 11565518, 11832527, 12122111, 12202461, 12612578, 14525967,
14706052, 15016488, 15043959, 15266224, 15325833, 15356308, 15551269`.

**Outcome: all 15 CLEAN.** None of these papers have PMC full text available, so
the check is a metadata-match only (same approach used in prior runs since the
sandbox cannot fetch paywalled fulltext). All abstract-level metadata exactly
matches PubMed authoritative source for each PMID.

### 2. Gap #14 Audit (early, originally due 2026-05-26)
"Personalized Nutrition Strategy for LADA" — searched for 2026 LADA-specific
nutrition RCTs. Only adjacent T2D/obesity work surfaced:
* PMID 41490780 (JMIR 2026) — overweight/obesity remote digital nutrition RCT, not LADA-specific.
* PMC9258630 (Front Nutr 2022) — Chinese adults BMI≥24, general personalized nutrition.
* NCT00776607 — LADA insulin-vs-tablets, no nutrition arm.

**Outcome: BRONZE retained.** Independent secondary LADA-specific source still
absent. Next audit 2026-06-26.

### 3. Topic Check — DAPAN-DIA (NCT06047262)
Multicenter Switzerland/France/Belgium/Germany; 300 T2D pts; HbA1c primary at 6mo.
Latest scientific disclosure remains AHA abstract 4115645 (Circulation 2024
design paper). Trial still enrolling; no peer-reviewed efficacy data.
**Outcome: no change.** Next check 2026-08-20.

### 4. Credibility Sweep
* No PMIDs above 42000000 in any script.
* No "zero SAEs" / "zero rejection" overclaims.
* All "cure"/"curative" mentions are appropriately framed: category labels,
  search-term constants, EML/policy context, or properly tiered BRONZE
  preclinical (Stanford hybrid immune-system mouse study explicitly labeled
  "single preclinical study in mice; human translation uncertain").
**Outcome: CLEAN.**

### 5. Pipeline Rebuild
`python Analysis/Scripts/run_quality_improvements.py` — **41/41 [OK]**.

## Cumulative Progress
| Metric | Before | After |
|---|---|---|
| Papers total | 283 | 283 |
| VETTED | 270 | 270 |
| FLAGGED | 13 | 13 |
| Claims-checked | 158 | 173 (+15) |
| VETTED-no-claims remaining | 120 | 105 |

At the current cadence (~12-15 papers/run), the remaining 105 papers will be
fully claims-checked in ~7-9 more runs (~2 weeks). The doctrine target of "all
papers vetted within 2 weeks of entering the system" remains on track.

## Queue Updates
* Removed: 2026-05-19 vet_papers_batch item (processed).
* Added: 2026-05-21 vet_papers_batch — next 12 PMIDs
  `15793177, 15919781, 15919794, 15928679, 16214598, 16310551, 16731815,
  16898223, 17005949, 21323736, 21372320, 21864487`.
* Updated: claims_check_batch progress note.
* Gap #14 next audit date pushed to 2026-06-26 (since handled early).

## Open Items
* **Manual git push required** — sandbox lacks GitHub auth. After this commit
  there will be 15 unpushed commits (oldest from ~2026-04-21). User should run
  `git push` from PowerShell on local machine.
* Item #5 (claims_check_batch) and item #20 → next vet_papers_batch remain the
  bulk of the recurring work for next ~9 runs.

